<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SOTALOL HYDROCHLORIDE- sotalol hydrochloride injection </strong><br>Mylan Institutional LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use sotalol hydrochloride injection safely and effectively. See full prescribing information for sotalol hydrochloride injection. <br> <br>SOTALOL hydrochloride injection for intravenous use<br>Initial U.S. Approval: 1992</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: LIFE THREATENING <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">PROARRHYTHMIA</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning</span>.</span></h1>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Sotalol can cause life threatening <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> associated with QT interval prolongation</span>.</dd>
<dt>•</dt>
<dd><span class="Bold">Do not initiate sotalol therapy if the baseline QTc is longer than 450 ms. If the QT interval prolongs to 500 ms or greater, the dose must be reduced, the duration of the infusion prolonged or the drug discontinued.</span></dd>
<dt>•</dt>
<dd>
<span class="Bold">Patient should be hospitalized in a facility that can provide cardiac resuscitation and continuous electrocardiographic monitoring</span>.</dd>
<dt>•</dt>
<dd><span class="Bold">Adjust the dosing interval based on creatinine clearance.</span></dd>
</dl>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: LIFE THREATENING <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">PROARRHYTHMIA</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning</span>.</span></h1>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Sotalol can cause life threatening <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> associated with QT interval prolongation</span>.</dd>
<dt>•</dt>
<dd><span class="Bold">Do not initiate sotalol therapy if the baseline QTc is longer than 450 ms. If the QT interval prolongs to 500 ms or greater, the dose must be reduced, the duration of the infusion prolonged or the drug discontinued.</span></dd>
<dt>•</dt>
<dd>
<span class="Bold">Patient should be hospitalized in a facility that can provide cardiac resuscitation and continuous electrocardiographic monitoring</span>.</dd>
<dt>•</dt>
<dd><span class="Bold">Adjust the dosing interval based on creatinine clearance.</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Sotalol hydrochloride for intravenous use is an antiarrhythmic agent indicated for: </p>
<dl>
<dt>•</dt>
<dd>Substitution for oral sotalol in patients who are unable to take sotalol orally (<a href="#i4i_section_id_649d0da2-e65b-41f3-a1f9-d6676303add5">1.1</a>)</dd>
</dl>
<p class="Highlighta">Oral sotalol is indicated for: </p>
<dl>
<dt>•</dt>
<dd>Maintenance of normal sinus rhythm in patients with history of highly symptomatic <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>/flutter (<a href="#i4i_section_id_22e6cd3e-6ef6-441d-8dd7-299dea7cddcd">1.2</a>)</dd>
<dt>•</dt>
<dd>Treatment of documented life-threatening <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> (<a href="#i4i_section_id_39183221-58a8-48db-aa55-94c36b1cc359">1.3</a>)</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Intravenous sotalol must be diluted. Appropriate diluents are saline, 5% dextrose in water (D5W), or Ringer's lactate. Intravenous sotalol is administered by a volumetric infusion pump over 5 hours at a constant infusion rate. See full prescribing information for general rules and safety measures (<a href="#i4i_section_id_ff8744bc-c584-44fa-8bf2-a761589c90c5">2.1</a>), dose selection (<a href="#i4i_section_id_04c488fc-3851-4349-a8d9-1e038b3489d6">2.2</a>) and preparation of infusion (<a href="#i4i_section_id_3123e354-dd2b-4960-9ad8-b7d044fe71a5">2.3</a>)  </p>
<p class="Highlighta"><span class="Bold">Maintenance of sotalol therapy – Replacement of Oral Dosing</span> </p>
<p class="Highlighta">The intravenous dose is approximately equal to the oral dose and administered at the same dosing frequency. 75 mg of intravenous sotalol is approximately equal to 80 mg of oral sotalol (<a href="#i4i_section_id_04c488fc-3851-4349-a8d9-1e038b3489d6">2.2</a>) </p>
<p class="Highlighta"><span class="Bold">Initiation of Therapy</span> </p>
<dl>
<dt>•</dt>
<dd>Calculate creatinine clearance to determine dosing interval (<a href="#i4i_section_id_ff8744bc-c584-44fa-8bf2-a761589c90c5">2.1</a>)</dd>
<dt>•</dt>
<dd>Starting adult dose is 75 mg administered twice daily. If creatinine clearance is between 60 and 40 mL/min, administer once daily, if less than 40 mg/mL, sotalol is not recommended (<a href="#i4i_section_id_ff8744bc-c584-44fa-8bf2-a761589c90c5">2.1</a>)</dd>
<dt>•</dt>
<dd>The dose can be up-titrated to maximal dose of 150 mg twice daily under close ECG and QT interval monitoring (<a href="#i4i_section_id_4b371768-e394-441d-8f46-339cd17325d3">2.5</a>, <a href="#i4i_section_id_b43d3237-c711-412d-884d-880c8d741b25">2.6</a>)</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>150 mg sotalol hydrochloride in 10 mL vial (15 mg/mL) (Must be diluted prior to use)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus bradycardia</span> (&lt;50 bpm), <span class="product-label-link" type="condition" conceptid="317302" conceptname="Sinus node dysfunction">sick sinus syndrome</span> or 2<span class="Sup">nd</span> and 3<span class="Sup">rd</span> degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> unless a functioning pacemaker is present (<a href="#i4i_contraindications_id_44db7e75-61e1-4ac6-a0d3-caefd0cea7b3">4</a>)</dd>
<dt>•</dt>
<dd>Congenital or acquired <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndromes</span>, QT interval &gt;450 ms (<a href="#i4i_contraindications_id_44db7e75-61e1-4ac6-a0d3-caefd0cea7b3">4</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">Cardiogenic shock</span>, uncontrolled <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (<a href="#i4i_contraindications_id_44db7e75-61e1-4ac6-a0d3-caefd0cea7b3">4</a>)</dd>
<dt>•</dt>
<dd>Creatinine clearance &lt;40 mL/min (<a href="#i4i_contraindications_id_44db7e75-61e1-4ac6-a0d3-caefd0cea7b3">4</a>)</dd>
<dt>•</dt>
<dd>Serum potassium &lt;4 meq/L (<a href="#i4i_contraindications_id_44db7e75-61e1-4ac6-a0d3-caefd0cea7b3">4</a>)</dd>
<dt>•</dt>
<dd>Bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or related bronchospastic conditions (<a href="#i4i_contraindications_id_44db7e75-61e1-4ac6-a0d3-caefd0cea7b3">4</a>)</dd>
<dt>•</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to sotalol (<a href="#i4i_contraindications_id_44db7e75-61e1-4ac6-a0d3-caefd0cea7b3">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>QT prolongation and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">proarrhythmia</span>: Reduce dose, reduce rate of infusion, or discontinue (<a href="#i4i_section_id_c31b0aa7-3017-4b39-b23a-bbfe8f0fcdbf">5.1</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, worsening <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>: Reduce dose as needed (<a href="#i4i_section_id_ac53999a-095a-4159-99be-9269b85fdd0d">5.3</a>, <a href="#i4i_section_id_5d2e2b09-d113-46a6-814d-8d2c6cefa654">5.4</a>, <a href="#i4i_section_id_86a1dfb9-83cd-4a32-a1eb-2b6a7a1a5a3f">5.5</a>. <a href="#i4i_section_id_b42ae473-7d37-4be4-a0fc-9cacedddd2d8">5.6</a>)</dd>
<dt>•</dt>
<dd>Acute exacerbation of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> upon cessation of therapy: Do not abruptly discontinue (<a href="#i4i_section_id_aa48b0b3-58af-4fa8-b69b-2804026bf05f">5.8</a>) </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte disturbances</span> must be corrected (<a href="#i4i_section_id_f14d001b-3afc-4db8-ad98-da3faa4413cf">5.9</a>)</dd>
<dt>•</dt>
<dd>Monitor serum glucose in diabetic patients as sotalol may mask symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, or worsen <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> (<a href="#i4i_section_id_6f7b6c36-0b13-4018-943f-b0c53853d648">5.12</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (&gt;10%) seen with oral sotalol (dose related) are <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, and <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span> (<a href="#i4i_section_id_b7c9c4a5-ef1d-419c-a170-9e1f985b49d1">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact DRUG SAFETY at 1-888-875-1671 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Digoxin increases the risk of proarrhythmic events (<a href="#i4i_section_id_40ea58e7-81f4-40f0-b682-7c31ed300f9c">7.1</a>)</dd>
<dt>•</dt>
<dd>Calcium blocking drugs may have additive effects on decreasing atrioventricular conduction, ventricular function, and blood pressure (<a href="#i4i_section_id_9eb92c62-4feb-40a0-8592-17dc3e88dcb1">7.2</a>)</dd>
<dt>•</dt>
<dd>Concomitant use of catecholamine-depleting drugs may produce <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, marked <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (<a href="#i4i_section_id_ed782acd-13c1-4e6b-8ac1-c8672ea43ef4">7.3</a>)</dd>
<dt>•</dt>
<dd>Dosage of insulin or antidiabetic drugs may require adjustment (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>). Symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may be masked (<a href="#i4i_section_id_1809d34a-9e6f-46cf-8199-4f8b6d17ad83">7.4</a>)</dd>
<dt>•</dt>
<dd>Dose of beta-2 receptor agonists may have to be increased (<a href="#i4i_section_id_85751bf5-7492-40f0-a7a4-283a8ac689fd">7.5</a>)</dd>
<dt>•</dt>
<dd>Sotalol may potentiate the <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">rebound hypertension</span> after discontinuation of clonidine (<a href="#i4i_section_id_54326d32-03a6-4901-85ad-2cc0ffe0c4a3">7.6</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Nursing mothers: Sotalol is excreted in milk in large amounts; potential harm to the infants. Discontinue nursing or discontinue the drug (<a href="#i4i_nursing_mothers_id_2296f421-39f3-4747-8df8-7a7c2d6d4f9f">8.3</a>)</dd>
</dl></div>
<div><div></div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 9/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: LIFE THREATENING <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">PROARRHYTHMIA</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Substitution for Oral Sotalol Therapy</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Delay in Recurrence of <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span>/<span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">Atrial Flutter</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Documented Life-Threatening <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular Arrhythmia</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 General Rules and Safety Measures of Intravenous Sotalol Therapy</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dose of Intravenous Sotalol</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Preparation of Sotalol Infusion</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Initiation of Intravenous Sotalol Therapy</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Upward Titration of Dose</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Dose for <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular Arrhythmias</span></a></h2>
<h2><a href="#section-2.7" class="toc">2.7 Dose for Symptomatic <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL</a></h2>
<h2><a href="#section-2.8" class="toc">2.8 Dosing and Administration in Children</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 QT Prolongation and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Proarrhythmia</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>/<span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">Heart Block</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="317302" conceptname="Sinus node dysfunction">Sick Sinus Syndrome</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Recent Acute MI</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Abrupt Withdrawal</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Disturbances</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Non-<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Allergic Bronchospasm</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></a></h2>
<h2><a href="#section-5.13" class="toc">5.13 <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span></a></h2>
<h2><a href="#section-5.14" class="toc">5.14 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></a></h2>
<h2><a href="#section-5.15" class="toc">5.15 Anesthesia</a></h2>
<h2><a href="#section-5.16" class="toc">5.16 Drug/Laboratory Test Interactions</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Digoxin</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Calcium Blocking Drugs</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Catecholamine-Depleting Agents</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Insulin and Oral Antidiabetic Agents</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Beta-2-Receptor Stimulants</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Clonidine</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Drugs that Prolong QT Interval and Antiarrhythmic Agents</a></h2>
<h2><a href="#section-7.8" class="toc">7.8 Other</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Clinical Studies in <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular Arrhythmias</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Clinical Studies in Supra-<span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular Arrhythmias</span></a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Clinical Studies in Patients with <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="box"></a><a name="section-1"></a><p></p>
<h1>WARNING: LIFE THREATENING <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">PROARRHYTHMIA</span></h1>
<p class="First"><span class="Bold">To minimize the risk of induced <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, patients initiated or re-initiated on intravenous sotalol, and patients who are converted from intravenous to oral administration should be hospitalized in a facility that can provide cardiac resuscitation, continuous electrocardiographic monitoring and calculations of creatinine clearance.</span></p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Sotalol can cause life threatening <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> associated with QT interval prolongation</span></dd>
<dt>•</dt>
<dd><span class="Bold">Do not initiate sotalol therapy if the baseline QTc is longer than 450 ms. If the QT interval prolongs to 500 ms or greater, the dose must be reduced, the duration of the infusion prolonged or the drug discontinued</span></dd>
<dt>•</dt>
<dd><span class="Bold">Adjust the dosing interval based on creatinine clearance</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_c8bedc43-a1a5-4b87-9d33-56ef273a9ab0"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_649d0da2-e65b-41f3-a1f9-d6676303add5"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Substitution for Oral Sotalol Therapy</h2>
<p class="First">Intravenous sotalol can substitute for oral sotalol in patients who are unable to take sotalol orally. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_22e6cd3e-6ef6-441d-8dd7-299dea7cddcd"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Delay in Recurrence of <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span>/<span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">Atrial Flutter</span></h2>
<p class="First">Sotalol is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>/<span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span> (<span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL)] in patients with symptomatic <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL who are currently in sinus rhythm. Because sotalol can cause life-threatening <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, it should be reserved for patients in whom <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL is highly symptomatic. Patients with paroxysmal <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span> whose <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL is easily reversed (by Valsalva maneuver, for example) should usually not be given sotalol. In general, antiarrhythmic therapy for <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL aims to prolong the time in normal sinus rhythm. Recurrence is expected in some patients <span class="Italics">[see <a href="#i4i_section_id_9a70ce44-6aa5-4ba7-9f58-2abc92d9cb22">Clinical Studies (14.2)</a>]</span>. </p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> should be anticoagulated according to usual medical practice.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_39183221-58a8-48db-aa55-94c36b1cc359"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Documented Life-Threatening <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular Arrhythmia</span></h2>
<p class="First">Sotalol is indicated for the treatment of documented life-threatening <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>. Because of the <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">proarrhythmic effects</span> of sotalol<span class="Italics"> [see <a href="#i4i_section_id_c31b0aa7-3017-4b39-b23a-bbfe8f0fcdbf">Warnings and Precautions (5.1)</a>]</span> including a 1.5 to 2% rate of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span> or new VT/VF in patients with either NSVT or supraventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, its use in patients with less severe <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, even if the patients are symptomatic, is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. In life-threatening <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, the response to treatment should then be evaluated by a suitable method (e.g., PES or Holter monitoring) at steady state blood levels of drug prior to continuing the patient on chronic therapy. Antiarrhythmic drugs may not enhance survival in patients with <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_19f282cf-4239-480c-bf7d-632e7494b94b"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ff8744bc-c584-44fa-8bf2-a761589c90c5"></a><a name="section-2.1"></a><p></p>
<h2>2.1 General Rules and Safety Measures of Intravenous Sotalol Therapy</h2>
<p class="First">For the safety of the patient, the safety measures required of oral sotalol administration must also be applied for intravenous route. To minimize the risk of induced <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, patients initiated or re-initiated on sotalol should be hospitalized for at least three days or until steady state drug levels are achieved, in a facility that can provide cardiac resuscitation and continuous electrocardiographic monitoring. Initiate intravenous sotalol therapy in the presence of personnel trained in the management of serious <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>. Perform a baseline ECG to determine the QT interval and measure and normalize serum potassium and magnesium levels before initiating therapy with starting sotalol injection. Measure serum creatinine and calculate an estimated creatinine clearance in order to establish the appropriate dosing interval for sotalol.</p>
<p>If the baseline QT is greater than 450 ms (JT &gt;330 ms if QRS over 100 ms), sotalol is not recommended.</p>
<p>The patient's creatinine clearance should be calculated using the one of several formulas. The Cockcroft-Gault formula to determine creatinine clearance is: </p>
<table>
<col width="50%">
<col width="50%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"><p class="First">Creatinine clearance (male) =</p></td>
<td class="Toprule"><p class="First"><span class="Underline">(140-age) × body weight in kg </span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First">72 × serum creatinine (mg/dL)</p></td>
</tr>
<tr>
<td><p class="First">Creatinine clearance (female) =</p></td>
<td><p class="First"><span class="Underline">(140-age) × body weight in kg ×0.85 </span></p></td>
</tr>
<tr class="Last">
<td class="Botrule"></td>
<td class="Botrule"><p class="First">72 × serum creatinine (mg/dL)</p></td>
</tr>
</tbody>
</table>
<p>When serum creatinine is given in µmol/L, divide the value by 88.4 (1 mg/dL = 88.4 µmol/L).</p>
<p>Start sotalol therapy only if the baseline QT interval is &lt;450 ms. During initiation and titration, monitor the QT interval after the completion of each infusion If the QT interval prolongs to 500 ms or greater, reduce the dose, decrease the infusion rate, or discontinue the drug.</p>
<p>Administer sotalol twice daily in patients with a creatinine clearance &gt;60 mL/min or once daily) in patients with a creatinine clearance between 40 and 60 mL/min. Sotalol is not recommended in patients with a creatinine clearance &lt;40 mL/min. The recommended initial IV dose of sotalol is 75 mg (once or twice daily) and is initiated as shown in the dosing algorithm described below. The 75 mg dose can be titrated upward to 112.5 or 150 mg after at least 3 days <span class="Italics">[see <a href="#i4i_section_id_4b371768-e394-441d-8f46-339cd17325d3">Dosage and Administration (2.5)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_04c488fc-3851-4349-a8d9-1e038b3489d6"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dose of Intravenous Sotalol</h2>
<p class="First">The bioavailability of oral sotalol is between 90% and 100%. The corresponding dose of intravenous sotalol is, therefore, slightly less than that of the oral dose. The effects of the initial intravenous dose must be monitored and the dose titrated either upward or downward, if needed, based on clinical effect, QT interval, or adverse reactions.</p>
<a name="_Reftable1"></a><table>
<caption><span>Table 1: Conversion from Oral Sotalol to Intravenous Sotalol</span></caption>
<col width="40%">
<col width="60%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" valign="top">
<span class="Bold">Oral dose</span><br><span class="Bold">Once or twice daily</span>
</th>
<th class="Botrule Rrule Toprule" valign="top">
<span class="Bold">Intravenous dose</span><br><span class="Bold">Once or twice daily</span><br><span class="Bold">Administered over 5 hours</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">80 mg</span></p></td>
<td class="Botrule Rrule Toprule"><p class="First"><span class="Bold">75 mg (5 mL sotalol injection)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">120 mg</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">112.5 mg (7.5 mL sotalol injection)</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">160 mg</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">150 mg (10 mL sotalol injection)</span></p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3123e354-dd2b-4960-9ad8-b7d044fe71a5"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Preparation of Sotalol Infusion</h2>
<p class="First">Intravenous sotalol must be diluted for infusion. Appropriate diluents are saline, 5% dextrose in water (D5W), or Ringer's lactate. Usually, prepare in a volume of 100-250 mL. Use a volumetric infusion pump to infuse intravenous sotalol at a constant rate. The following table compensates for dead space in the infusion set.</p>
<a name="_Reftable2"></a><table>
<caption><span>Table 2: Sotalol Infusion Preparation to Compensate for Dead Space in Infusion Set</span></caption>
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" valign="top">
<span class="Bold">Target</span><br><span class="Bold"> Dose</span>
</th>
<th class="Botrule Rrule Toprule" valign="top"><span class="Bold">Sotalol Injection</span></th>
<th class="Botrule Rrule Toprule" valign="top"><span class="Bold">Diluent</span></th>
<th class="Botrule Rrule Toprule" valign="top">
<span class="Bold">Volume</span><br><span class="Bold"> Prepared</span>
</th>
<th class="Botrule Rrule Toprule" valign="top">
<span class="Bold">Volume</span><br><span class="Bold"> to Infuse</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">75 mg</span></p></td>
<td class="Botrule Rrule Toprule"><p class="First"><span class="Bold">6 mL</span></p></td>
<td class="Botrule Rrule Toprule"><p class="First"><span class="Bold">114 mL</span></p></td>
<td class="Botrule Rrule Toprule" rowspan="3"><p class="First"><span class="Bold">120 mL</span></p></td>
<td class="Botrule Rrule Toprule"><p class="First"><span class="Bold">100 mL</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">112.5 mg</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">9 mL</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">111 mL</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">100 mL</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">150 mg</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">12 mL</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">108 mL</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">100 mL</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5"><p class="First"> </p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">75 mg</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">6 mL</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">294 mL</span></p></td>
<td class="Botrule Rrule" rowspan="3"><p class="First"><span class="Bold">300 mL</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">250 mL</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">112.5 mg</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">9 mL</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">291 mL</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">250 mL</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">150 mg</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">12 mL</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">288 mL</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">250 mL</span></p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_54211227-3b32-496d-9865-d6cb92aa089d"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Initiation of Intravenous Sotalol Therapy</h2>
<p class="First">The starting dose of intravenous sotalol is 75 mg infused over 5 hours once or twice daily based on the creatinine clearance. Monitor ECG for excessive increase in QTc.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4b371768-e394-441d-8f46-339cd17325d3"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Upward Titration of Dose</h2>
<p class="First">If the 75 mg dose of intravenous sotalol does not reduce the frequency of relapses of life threatening <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> or symptomatic <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL and is tolerated without excessive (i.e., to &gt;500 ms) QTc prolongation, increase the dose to 112.5 mg infused over 5 hours, once or twice daily depending upon the creatinine clearance. Continue to monitor QTc during dose escalations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b43d3237-c711-412d-884d-880c8d741b25"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Dose for <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular Arrhythmias</span></h2>
<p class="First">The recommended initial dose of intravenous sotalol is 75 mg infused over 5 hours, once or twice daily based on creatinine clearance. The dose may be increased in increments of 75 mg/day every 3 days. The usual therapeutic effect is observed with oral doses of 80 to 160 mg once or twice a day (corresponding to 75 to 150 mg intravenous sotalol). Oral doses as high as 240-320 mg once or twice a day (corresponding to 225 to 300 mg intravenous sotalol) have been utilized in patients with refractory life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8ea455a8-0e80-466a-a08b-f65fe7a4c06d"></a><a name="section-2.7"></a><p></p>
<h2>2.7 Dose for Symptomatic <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL</h2>
<p class="First">In the U.S. multicenter dose-response study, 120 mg orally once or twice a day (corresponding to 112.5 mg intravenous sotalol) was found to be the most effective dose in prolonging the time to ECG-documented symptomatic recurrence of <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL. If that dose level, at steady state, does not reduce the frequency of early relapse of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> and is tolerated without excessive QTc prolongation (&gt;520 ms), increase the dose to 160 mg orally once or twice a day (corresponding to 150 mg intravenous sotalol). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_30d58659-06a9-4aa7-bf41-adf4709d5235"></a><a name="section-2.8"></a><p></p>
<h2>2.8 Dosing and Administration in Children</h2>
<p class="First">Intravenous sotalol has not been studied in children. As in adults the following precautionary measures should be considered when initiating sotalol treatment in children: initiation of treatment in the hospital after appropriate clinical assessment; individualized regimen as appropriate; gradual increase of doses if required; careful assessment of therapeutic response and tolerability; and frequent monitoring of the QTc interval and heart rate. </p>
<p>For children aged about 2 years and greater, with normal renal function, doses normalized for body surface area are appropriate for both initial and incremental dosing. Since the Class III potency in children <span class="Italics">[see <a href="#i4i_pharmacodynamics_id_c8a4f3eb-e032-4397-ab51-aae3a35c3b34">Clinical Pharmacology (12.2)</a>]</span> is not very different from that in adults, reaching plasma concentrations that occur within the adult dose range is an appropriate guide. From pediatric pharmacokinetic data the following is recommended. For initiation of treatment, 30 mg/m<span class="Sup">2</span> three times a day (90 mg/m<span class="Sup">2</span> total daily dose) is approximately equivalent to the initial 160 mg total oral daily dose for adults. Subsequent titration to a maximum of 60 mg/m<span class="Sup">2</span> (approximately equivalent to the 360 mg total daily dose for adults) can then occur. Titration should be guided by clinical response, heart rate and QTc, with increased dosing being carried out in-hospital. At least 36 hours should be allowed between dose increments to attain steady-state plasma concentrations of sotalol in patients with age-adjusted normal renal function. </p>
<p>For children about 2 years or younger the above pediatric dosage should be reduced by a factor that depends heavily upon age, as shown in the following graph which shows age plotted on a logarithmic scale in months. </p>
<div class="Figure">
<a name="id539"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2afe7385-2441-4e22-b63e-ab8614b275df&amp;name=1a9b03b5-4401-4e83-bfef-53ba0434e846-01.jpg">
</div>
<p>For a child aged 20 months, the dosing suggested for children with normal renal function aged 2 years or greater should be multiplied by about 0.97; the initial starting dose would be (30 × 0.97) = 29.1 mg/m<span class="Sup">2</span>, administered orally three times daily. For a child aged 1 month, the starting dose should be multiplied by 0.68; the initial starting dose would be (30 × 0.68) = 20 mg/m<span class="Sup">2</span>, administered orally three times daily. For a child aged 1 week, the initial starting oral dose should be multiplied by 0.3; the starting dose would be (30 × 0.3) = 9 mg/m<span class="Sup">2</span>. Similar calculations should be made for increased doses as titration proceeds. Since the half-life of sotalol decreases with decreasing age (below about 2 years), time to steady-state will also increase. Thus, in neonates the time to steady-state may be as long as a week or longer. </p>
<p>In all children, individualization of dosage is required. As in adults sotalol should be used with particular caution in children if the QTc is greater than 500 ms on therapy and serious consideration should be given to reducing the dose or discontinuing therapy when QTc exceeds 550 ms. </p>
<p>The use of oral sotalol in children with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> has not been investigated. Sotalol elimination is predominantly via the kidney in the unchanged form. Use of sotalol in any age group with decreased renal function should be at lower doses or at increased intervals between doses. Monitoring of heart rate and QTc is most important. It will take much longer to reach steady-state with any dose and/or frequency of administration in these children.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_a4bdfa48-01a9-433d-9941-1995430a6808"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">150 mg sotalol hydrochloride in 10 mL vial (15 mg/mL).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_44db7e75-61e1-4ac6-a0d3-caefd0cea7b3"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus bradycardia</span> (&lt;50 bpm), <span class="product-label-link" type="condition" conceptid="317302" conceptname="Sinus node dysfunction">sick sinus syndrome</span> or second or <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">third degree AV block</span> unless a functioning pacemaker is present</dd>
<dt>•</dt>
<dd>Congenital or acquired <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndromes</span>, QT interval &gt;450 ms</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">Cardiogenic shock</span>, uncontrolled <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span></dd>
<dt>•</dt>
<dd>Creatinine clearance &lt;40 mL/min</dd>
<dt>•</dt>
<dd>Serum potassium &lt;4 meq/L</dd>
<dt>•</dt>
<dd>Bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or related bronchospastic conditions</dd>
<dt>•</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to sotalol</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_ad20e534-fe78-4ebc-859c-1ba09590bed1"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c31b0aa7-3017-4b39-b23a-bbfe8f0fcdbf"></a><a name="section-5.1"></a><p></p>
<h2>5.1 QT Prolongation and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Proarrhythmia</span></h2>
<p class="First">Sotalol can cause serious <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, primarily <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span> (TdP) type <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, a <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">polymorphic ventricular tachycardia</span> associated with QTc prolongation. QTc prolongation is directly related to the concentration of sotalol. Factors such as reduced creatinine clearance, gender (female) and larger doses increase the risk of TdP. The risk of TdP can be reduced by adjustment of the sotalol dose according to creatinine clearance and by monitoring the ECG for excessive increases in QTc. </p>
<p>Initiate sotalol only in a facility that can provide ECG monitoring and in the presence of personnel trained in the management of serious <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>. Steady-state plasma levels of sotalol and maximum QTc prolongation occur by 3 days. Calculation of the creatinine clearance must precede administration of the first dose of sotalol. For detailed instructions regarding dose selection <span class="Italics">[see <a href="#i4i_dosage_admin_id_19f282cf-4239-480c-bf7d-632e7494b94b">Dosage and Administration (2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_05ebb99b-2f38-41e1-b238-8b2c0d847ae3"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents</h2>
<p class="First">The use of sotalol in conjunction with other drugs that prolong the QT interval has not been studied and is not recommended. Such drugs include many antiarrhythmics, some phenothiazines, tricyclic antidepressants, and certain oral macrolides. Class I or Class III antiarrhythmic agents should be withheld for at least three half-lives prior to dosing with sotalol. In clinical trials, sotalol was not administered to patients previously treated with oral amiodarone for &gt;1 month in the previous three months. Class Ia antiarrhythmic drugs, such as disopyramide, quinidine and procainamide and other Class III drugs (e.g., amiodarone) are not recommended as concomitant therapy with intravenous sotalol because of their potential to prolong refractoriness. There is only limited experience with the concomitant use of Class Ib or Ic antiarrhythmics. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ac53999a-095a-4159-99be-9269b85fdd0d"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>/<span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">Heart Block</span></h2>
<p class="First">In studies of oral sotalol, the incidence of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> (as determined by the investigators) in the supraventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> population treated with oral sotalol was 13% and led to discontinuation in 2.4%. <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> itself increases the risk of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span>, so carefully monitor patients receiving concomitant digoxin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5d2e2b09-d113-46a6-814d-8d2c6cefa654"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="317302" conceptname="Sinus node dysfunction">Sick Sinus Syndrome</span></h2>
<p class="First">In general, sotalol is not recommended in patients with <span class="product-label-link" type="condition" conceptid="317302" conceptname="Sinus node dysfunction">sick sinus syndrome</span> associated with symptomatic <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, because it may cause <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>, sinus pauses, or <span class="product-label-link" type="condition" conceptid="4210313" conceptname="Sinus arrest">sinus arrest</span>. In patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span> and sinus node dysfunction, sotalol increases the risk of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span>, especially after cardioversion. Sotalol augments <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and QTc prolongation following cardioversion. Patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL associated with the <span class="product-label-link" type="condition" conceptid="317302" conceptname="Sinus node dysfunction">sick sinus syndrome</span> may be treated with sotalol if they have an implanted pacemaker for control of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> symptoms. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_86a1dfb9-83cd-4a32-a1eb-2b6a7a1a5a3f"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h2>
<p class="First">Sotalol produces significant reductions in both systolic and diastolic blood pressures and may result in <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. Although sotalol is usually well-tolerated, monitor hemodynamics in patients with marginal cardiac compensation as deterioration in cardiac performance may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b42ae473-7d37-4be4-a0fc-9cacedddd2d8"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></h2>
<p class="First">Sympathetic stimulation is necessary in supporting circulatory function in <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, and beta-blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In a pooled data base of four placebo-controlled <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL and PSVT studies, new or worsening <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> occurred during therapy with oral sotalol in 5 (1.2%) of 415 patients. In these studies patients with uncontrolled <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> were excluded (i.e., NYHA Functional Classes III or IV).</p>
<p>In other premarketing oral sotalol studies, new or worsened <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> occurred in 3% of patients and led to discontinuation in approximately 1% of patients receiving sotalol. The incidence was higher in patients presenting with <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">sustained ventricular tachycardia</span>/<span class="product-label-link" type="condition" conceptid="4226399" conceptname="Fibrillation">fibrillation</span> (5%), or a prior history of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (7%). Based on a life-table analysis, the one-year incidence of new or worsened <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> was 3% in patients without a prior history and 10% in patients with a prior history of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2f2eb9ea-9e77-424a-be96-2b96d975b18c"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Recent Acute MI</h2>
<p class="First">Oral sotalol has been used in a controlled trial following an <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> without evidence of increased mortality <span class="Italics">[see <a href="#i4i_section_id_755ac418-2b7a-4cab-8fc3-e197ea59723f">Clinical Studies (14.3)</a>]</span>. Although specific studies of its use in treating <span class="product-label-link" type="condition" conceptid="4021776" conceptname="Atrial rhythm">atrial arrhythmias</span> after <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> have not been conducted, the usual precautions regarding <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, avoidance of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> or prolonged QT interval apply. Experience in the use of sotalol to treat <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> in the early phase of recovery from acute MI is limited. In the first 2 weeks post-MI careful dose titration is especially important, particularly in patients with markedly impaired ventricular function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aa48b0b3-58af-4fa8-b69b-2804026bf05f"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Abrupt Withdrawal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to catecholamines has been observed in patients withdrawn from beta-blocker therapy. Occasional cases of exacerbation of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> and, in some cases, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> have been reported after abrupt discontinuation of beta-blocker therapy. Therefore, when discontinuing chronically administered sotalol, particularly in patients with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, carefully monitor the patient and consider the temporary use of an alternative beta-blocker if appropriate. If possible, the dosage of sotalol should be gradually reduced over a period of one to two weeks. If angina or acute coronary insufficiency develops, appropriate therapy should be instituted promptly. Patients should be warned against interruption or discontinuation of therapy without the physician's advice. Because <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> is common and may be unrecognized in patients receiving sotalol, abrupt discontinuation in patients with <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> may unmask latent coronary insufficiency.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f14d001b-3afc-4db8-ad98-da3faa4413cf"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Disturbances</span></h2>
<p class="First">Sotalol should not be used in patients with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> prior to correction of imbalance, as these conditions increase the potential for <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span>. Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or patients receiving concomitant diuretic drugs. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ab4db066-6a95-4098-9145-0afb14acbc6f"></a><a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Sotalol is eliminated principally via the kidneys through glomerular filtration and to a small degree by tubular secretion. There is a direct relationship between renal function, as measured by serum creatinine or creatinine clearance, and the elimination rate of sotalol <span class="Italics">[see <a href="#i4i_dosage_admin_id_19f282cf-4239-480c-bf7d-632e7494b94b">Dosage and Administration (2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f158fe27-79af-4f04-88e4-b3eab3f81e3c"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Non-<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Allergic Bronchospasm</span></h2>
<p class="First">Patients with bronchospastic diseases should, in general, not receive beta-blockers. If sotalol is to be administered, use the smallest effective dose, to minimize inhibition of bronchodilation produced by endogenous or exogenous catecholamine stimulation of beta<span class="Sub">2 </span>receptors. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6f7b6c36-0b13-4018-943f-b0c53853d648"></a><a name="section-5.12"></a><p></p>
<h2>5.12 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></h2>
<p class="First">Beta-blockade may mask some important premonitory signs of acute <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (especially labile <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) or with a history of episodes of spontaneous <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3e7c9f85-4403-4ac4-bf44-a4e3a21fa8e7"></a><a name="section-5.13"></a><p></p>
<h2>5.13 <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span></h2>
<p class="First">Beta-blockade may mask certain clinical signs (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>. Avoid abrupt withdrawal of beta-blockade which might be followed by an exacerbation of symptoms of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, including <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid storm</span>. The beta-blocking effects of sotalol may be useful in controlling heart rate in <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span> associated with <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span>, but no study has been conducted to evaluate this. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6d079ae3-bca4-4a66-9186-1ffea6f209be"></a><a name="section-5.14"></a><p></p>
<h2>5.14 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></h2>
<p class="First">While taking beta-blockers, patients with a history of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat the <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f4a58783-5995-4526-a082-0e4c7f94e6db"></a><a name="section-5.15"></a><p></p>
<h2>5.15 Anesthesia</h2>
<p class="First">The management of patients undergoing major surgery who are being treated with beta-blockers is controversial. Protracted severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and difficulty in restoring and maintaining normal cardiac rhythm after anesthesia have been reported in patients receiving beta-blockers. </p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_582ee8dd-9f34-43c7-b67a-67d79ea43b16"></a><a name="section-5.16"></a><p></p>
<h2>5.16 Drug/Laboratory Test Interactions</h2>
<p class="First">The presence of sotalol in the urine may result in falsely elevated levels of urinary metanephrine when measured by fluorimetric or photometric methods. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_bcf0451c-aa8a-40d4-a033-6a3604493e9c"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b7c9c4a5-ef1d-419c-a170-9e1f985b49d1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">There is no clinical experience with intravenous sotalol. However, because of the similarity of exposure with intravenous sotalol and oral sotalol, the adverse reactions should be similar.</p>
<p>Adverse reactions that are clearly related to sotalol are those which are typical of its Class II (beta-blocking) and Class III (cardiac action potential duration prolongation) effects. The common documented beta-blocking adverse reactions (<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>) and Class III effects (QT interval prolongation) are dose related. </p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_06082141-f637-4d1e-afee-3fb661cad84d"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold">Serious Adverse Reactions</span></p>
<p>Sotalol can cause serious <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, primarily <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span> (TdP) type <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, a <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">polymorphic ventricular tachycardia</span> associated with QT interval prolongation. QT interval prolongation is directly related to the plasma level of sotalol. Factors such as reduced creatinine clearance, gender (female) and larger doses increase the risk of TdP <span class="Italics">[see <a href="#i4i_section_id_c31b0aa7-3017-4b39-b23a-bbfe8f0fcdbf">Warning and Precautions (5.1</a>]</span>. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8d7bf3bb-80e7-4554-8d93-be50630236bf"></a><a name="section-6.1.1.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Proarrhythmia</span> in <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span> Patients:</span> In eight controlled trials of patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL and other supraventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> (N=659) there were four cases of TdP reported (0.6%) during the controlled phase of treatment with oral sotalol. </p>
<p>Prolongation of the QT interval is dose related, increasing from baseline an average of 25, 40, and 50 ms in the 80, 120, and 160 mg groups, respectively, in the oral dose-response study. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_98c4c0d9-1648-46f8-902d-121df37e7b6c"></a><a name="section-6.1.1.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Proarrhythmia</span> in <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular Arrhythmia</span> Patients:</span> In patients with a history of <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">sustained ventricular tachycardia</span>, the incidence of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span> during oral sotalol treatment was 4% and worsened VT was about 1%; in patients with other less serious <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> the incidence of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span> was 1% and new or worsened VT was about 0.7%. Additionally, in approximately 1% of patients, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were considered possibly drug related; such cases, although difficult to evaluate, may have been associated with proarrhythmic events. <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> in patients with VT/VF were dose related, as was the prolongation of QT (QTc) interval, as shown in Table 1 below. </p>
<a name="_Reftable1a"></a><table>
<caption><span>Table 1: Percentage Incidence of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span> and Mean QTc Interval by Oral Dose for Patients with Sustained VT/VF</span></caption>
<col width="27%">
<col width="33%">
<col width="40%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" valign="top">
<span class="Bold">Daily Dose </span><br><span class="Bold">[mg] </span>
</th>
<th class="Botrule Rrule Toprule" valign="top">
<span class="Bold">Incidence of Torsade de </span><br><span class="Bold">Pointes </span>
</th>
<th class="Botrule Rrule Toprule" valign="top">
<span class="Bold">Mean QTc </span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><span class="Bold"> [ms] </span>
</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td class="Botrule" align="left" colspan="3" valign="top">( ) Number of patients assessed </td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>highest on-therapy value</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">80 </p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">0 (69) </p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">463 (17) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">160 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.5 (832) </p></td>
<td class="Botrule Rrule" align="center"><p class="First">467 (181) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">320 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.6 (835) </p></td>
<td class="Botrule Rrule" align="center"><p class="First">473 (344) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">480 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.4 (459) </p></td>
<td class="Botrule Rrule" align="center"><p class="First">483 (234) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">640 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.7 (324) </p></td>
<td class="Botrule Rrule" align="center"><p class="First">490 (185) </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">&gt;640 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.8 (103) </p></td>
<td class="Botrule Rrule" align="center"><p class="First">512 (62) </p></td>
</tr>
</tbody>
</table>
<p>Table 2 below relates the incidence of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span> to on-therapy QTc and change in QTc from baseline. It should be noted, however, that the highest on-therapy QTc was in many cases the one obtained at the time of the <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span> event, so that the table overstates the predictive value of a high QTc.</p>
<a name="_Reftable2a"></a><table>
<caption><span>Table 2: Relationship Between QTc Interval Prolongation and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span></span></caption>
<col width="25%">
<col width="25%">
<col width="25%">
<col width="25%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" valign="top">
<span class="Bold">On-Therapy </span><br><span class="Bold">QTc Interval </span><br><span class="Bold">[ms] </span>
</th>
<th class="Botrule Rrule Toprule" valign="top">
<span class="Bold">Incidence of </span><br><span class="Bold">Torsade de </span><br><span class="Bold">Pointes </span>
</th>
<th class="Botrule Rrule Toprule" valign="top">
<span class="Bold">Change in QTc </span><br><span class="Bold">Interval From </span><br><span class="Bold">Baseline [ms] </span>
</th>
<th class="Botrule Rrule Toprule" valign="top">
<span class="Bold">Incidence of </span><br><span class="Bold">Torsade de </span><br><span class="Bold">Pointes </span>
</th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="7" valign="top">( ) Number of patients assessed </td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">less than 500 </p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">1.3% (1787) </p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">less than 65 </p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">1.6% (1516) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">500-525 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.4% (236) </p></td>
<td class="Botrule Rrule" align="center"><p class="First">65-80 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.2% (158) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">525-550 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.6% (125) </p></td>
<td class="Botrule Rrule" align="center"><p class="First">80-100 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.1% (146) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&gt;550 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">10.8% (157) </p></td>
<td class="Botrule Rrule" align="center"><p class="First">100-130 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.2% (115) </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First">&gt;130 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">7.1% (99) </p></td>
</tr>
</tbody>
</table>
<p>In addition to dose and presence of sustained VT, other risk factors for <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span> were gender (females had a higher incidence), excessive prolongation of the QTc interval and history of <span class="product-label-link" type="condition" conceptid="314658" conceptname="Cardiomegaly">cardiomegaly</span> or <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Patients with <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">sustained ventricular tachycardia</span> and a history of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> appear to have the highest risk for serious <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">proarrhythmia</span> (7%). Of the <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span> patients experiencing <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span>, approximately two-thirds spontaneously reverted to their baseline rhythm. The others were either converted electrically (D/C cardioversion or overdrive pacing) or treated with other drugs <span class="Italics">[see <a href="#i4i_overdosage_id_c1cd81f0-6449-40d4-855a-132d339383d6">Overdosage (10)</a>]</span>. It is not possible to determine whether some <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden deaths</span> represented episodes of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span>, but in some instances <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> did follow a documented episode of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span>. Although sotalol therapy was discontinued in most patients experiencing <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span>, 17% were continued on a lower dose. </p>
<p>Nonetheless, intravenous sotalol should be used with particular caution if the QTc is greater than 500 ms on-therapy and serious consideration should be given to reducing the dose or discontinuing therapy when the QTc exceeds 520 ms. Proarrhythmic events must be anticipated not only on initiating therapy, but with every upward dose adjustment. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_657e9477-e026-4d10-95d7-cc4aa8764ba7"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold">Other Adverse Reactions</span></p>
<p>No data are available with intravenous sotalol. In a pooled clinical trial population consisting of four placebo-controlled studies with 275 patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL treated with 160-320 mg doses of oral sotalol the following adverse events were reported at a rate of 2% or more in the 160-240 mg treated patients and greater than the rate in placebo patients (See <a href="#_Reftable3">Table 3</a>). The data are presented by incidence of events in the sotalol and placebo groups by body system and daily dose. No significant irreversible non-cardiac end-organ toxicity was observed. </p>
<a name="_Reftable3"></a><table>
<caption><span>Table 3: Incidence (%) of Common Adverse Reactions (≥2% in the 160-240 mg group and more frequent than on placebo) in Four Placebo-Controlled Studies of Patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL Treated with Oral Sotalol</span></caption>
<col width="30%">
<col width="21%">
<col width="25%">
<col width="25%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" valign="top"></th>
<th class="Botrule Rrule Toprule" valign="middle"><span class="Bold"><span class="Underline"> Placebo </span></span></th>
<th class="Botrule Lrule Rrule Toprule" colspan="2" valign="top">
<span class="Bold">Sotalol </span><br><span class="Bold"><span class="Underline">Total Daily Dose</span></span>
</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" valign="bottom">
<span class="Bold">Body System/ </span><br><span class="Bold"> Adverse Reactions (Preferred Term) </span>
</th>
<th class="Botrule Rrule" valign="top"><span class="Bold">N=282 </span></th>
<th class="Botrule Rrule" valign="top">
<span class="Bold">160-240 </span><br><span class="Bold"> N=153 </span>
</th>
<th class="Botrule Lrule Rrule" valign="top">
<span class="Bold">&gt;240-320 </span><br><span class="Bold"> N=122 </span>
</th>
</tr>
</thead>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="4"><p class="First">CARDIOVASCULAR </p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.5 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">13.1 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">12.3 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  Disturbance Rhythm Subjective </p></td>
<td class="Botrule Rrule" align="center"><p class="First">9.9 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">9.8 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">7.4 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  Abnormality ECG </p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.4 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.3 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.5 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span> Cardiac/Non-Anginal </p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.6 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.6 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.5 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina Pectoris</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.1 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.0 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.6 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  Disturbance Rhythm Atrial </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.1 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.0 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.6 </p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First">GASTROINTESTINAL </p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.1 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.2 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.7 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.3 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">7.8 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.7 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Distention</span> Abdomen </p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.4 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.7 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.5 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>/<span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.8 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.0 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.5 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Abdomen </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.5 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.9 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.5 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Appetite Decreased</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.4 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.0 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.6 </p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First">GENERAL </p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">8.5 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">19.6 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">18.9 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.2 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.2 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.9 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.2 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.2 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.9 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.7 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.7 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.3 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  Sensation <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">Cold</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.7 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.0 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.5 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.4 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.0 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.8 </p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First">MUSCULOSKELETAL/CONNECTIVE TISSUE </p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Musculoskeletal </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.8 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.6 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.1 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Pain Chest</span> Musculoskeletal </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.4 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.0 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.5 </p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First">NERVOUS SYSTEM </p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">12.4 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">16.3 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">13.1 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.3 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.3 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">11.5 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.1 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.6 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.1 </p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First">RESPIRATORY </p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">7.4 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">9.2 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">9.8 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Infection Upper Respiratory</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.1 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.6 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.3 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4028970" conceptname="Tracheobronchitis">Tracheobronchitis</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.7 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.7 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.3 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.5 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.3 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.5 </p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First">SPECIAL SENSES </p></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">  Disturbance Vision </p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.7 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.6 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.8 </p></td>
</tr>
</tbody>
</table>
<p>Overall, discontinuation because of unacceptable adverse events was necessary in 17% of the patients, and occurred in 10% of patients less than two weeks after starting treatment. The most common adverse events leading to discontinuation of sotalol were: <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> 4.6%, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> 2.4%, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">proarrhythmia</span> 2.2%, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> 2%, and QT interval prolongation 1.4%. </p>
<p>In clinical trials involving 1292 patients with sustained VT/VF, the common adverse events (occurring in ≥2% of patients) were similar to those described for the <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL population. Table 4 lists as a function of dosage the most common (incidence of 2% or greater) adverse events, regardless of relationship to therapy and the percent of patients discontinued due to the event, as collected from clinical trials involving 1292 patients with sustained VT/VF.</p>
<a name="_Reftable4"></a><table>
<caption><span>Table 4: Incidence (%) of Adverse Events and Discontinuations (Disc) in 1292 patients with sustained VT/VF Receiving Oral Sotalol Therapy</span></caption>
<col width="34%">
<col width="8%">
<col width="8%">
<col width="8%">
<col width="8%">
<col width="8%">
<col width="9%">
<col width="16%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" valign="top"></th>
<th class="Botrule Rrule Toprule" colspan="6" valign="top"><span class="Bold">Daily Dose</span></th>
<th class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top">
<span class="Bold">%</span><br><span class="Bold"> Disc</span>
</th>
</tr>
<tr>
<th class="Botrule Lrule Rrule" valign="top"></th>
<th class="Botrule Rrule" valign="top"><span class="Bold">160 mg</span></th>
<th class="Botrule Rrule" valign="top"><span class="Bold">240 mg</span></th>
<th class="Botrule Rrule" valign="top"><span class="Bold">320 mg</span></th>
<th class="Botrule Rrule" valign="top"><span class="Bold">480 mg</span></th>
<th class="Botrule Rrule" valign="top"><span class="Bold">640 mg</span></th>
<th class="Botrule Lrule Rrule" valign="top">
<span class="Bold">Any Dose</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" valign="top"><span class="Bold">Body System</span></th>
<th class="Botrule Rrule" valign="top"><span class="Bold">n=832</span></th>
<th class="Botrule Rrule" valign="top"><span class="Bold">n=263</span></th>
<th class="Botrule Rrule" valign="top"><span class="Bold">n=835</span></th>
<th class="Botrule Rrule" valign="top"><span class="Bold">n=459</span></th>
<th class="Botrule Rrule" valign="top"><span class="Bold">n=324</span></th>
<th class="Botrule Rrule" valign="top"><span class="Bold">n=1292</span></th>
<th class="Botrule Lrule Rrule" valign="top"><span class="Bold">n=1292</span></th>
</tr>
</thead>
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Because patients are counted at each dose level tested, the Any Dose column cannot be determined by adding across the doses.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="8"><p class="First">BODY AS A WHOLE</p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Localized <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="8"><p class="First">CARDIOVASCULAR (CV)</p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Rrule" align="center"><p class="First">21</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">16</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">10</p></td>
<td class="Botrule Rrule" align="center"><p class="First">10</p></td>
<td class="Botrule Rrule" align="center"><p class="First">14</p></td>
<td class="Botrule Rrule" align="center"><p class="First">16</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitation</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">12</p></td>
<td class="Botrule Rrule" align="center"><p class="First">14</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="320536" conceptname="Electrocardiogram abnormal">ECG abnormal</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Proarrhythmia</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4142895" conceptname="Near syncope">Presyncope</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Periph vascular </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">CV disorder</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Vasodilation</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">AICD discharge</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="8"><p class="First">NERVOUS</p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">12</p></td>
<td class="Botrule Rrule" align="center"><p class="First">12</p></td>
<td class="Botrule Rrule" align="center"><p class="First">13</p></td>
<td class="Botrule Rrule" align="center"><p class="First">20</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Rrule" align="center"><p class="First">14</p></td>
<td class="Botrule Rrule" align="center"><p class="First">20</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">10</p></td>
<td class="Botrule Rrule" align="center"><p class="First">13</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Light-headed</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">12</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">Sleep problem</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Perspiration</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Altered consciousness</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Mood change</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Appetite disorder</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="8"><p class="First">DIGESTIVE</p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">10</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Colon problem</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="8"><p class="First">RESPIRATORY</p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Pulmonary problem</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Upper resp. tract problem</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="8"><p class="First">UROGENITAL</p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Genitourinary disorder</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Sex. dysfunction</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="8"><p class="First">METABOLIC</p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Abnormal lab</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Weight change</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="8"><p class="First">MUSCULOSKELETAL</p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Extremity <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="8"><p class="First">SKIN AND APPENDAGES</p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="8"><p class="First">HEMATOLOGIC</p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="8"><p class="First">SPECIAL SENSES</p></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Visual Problem</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt;1</p></td>
</tr>
</tbody>
</table>
<p>Occasional reports of elevated serum liver enzymes have occurred with sotalol therapy but no cause and effect relationship has been established. One case of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> which resolved on discontinuation of sotalol and recurred when the patient was rechallenged with the drug was reported in an early dose tolerance study. Elevated blood glucose levels and increased insulin requirements can occur in diabetic patients. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fc145701-b802-4d3d-963b-c2ec11c05c4a"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Bold">Pediatrics</span></p>
<p>There are no studies of intravenous sotalol in pediatric patients. In an unblinded multicenter trial of 25 pediatric patients with SVT and/or VT receiving daily oral doses of 30, 90 and 210 mg/m<span class="Sup">2 </span>with dosing every 8 hours for a total of 9 doses, no <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span> or other serious new <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> were observed. One (1) patient, receiving 30 mg/m<span class="Sup">2 </span>daily, was discontinued because of increased frequency of sinus pauses/<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. Additional cardiovascular AEs were seen at the 90 and 210 mg/m<span class="Sup">2 </span>daily dose levels. They included QT prolongations (2 patients), sinus pauses/<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> (1 patient), increased severity of <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span> and reported <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> (1 patient). Values for QTc ≥525 ms were seen in 2 patients at the 210 mg/m <span class="Sup">2 </span>daily dose level. Serious adverse events including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span>, other <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">proarrhythmias</span>, high-degree A-V blocks, and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> have been reported in infants and/or children. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_508f8da1-d73a-4ee5-a951-5184730e1969"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post approval use of sotalol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency of reporting, or strength of causal connection to the drug.</p>
<p>Postmarketing experience with sotalol shows an adverse reaction profile similar to that described above from clinical trials. Voluntary reports since introduction also include rare reports of: emotional liability, slightly clouded sensorium, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, pruritis, and <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>. </p>
<p>Foreign postmarketing experience with intravenous sotalol shows an adverse reaction profile similar to that described above from clinical trials. Sotalol related cardiovascular adverse events occurring in 1% or more of the patients are <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, ECG abnormalities, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">proarrhythmia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, and <span class="product-label-link" type="condition" conceptid="4142895" conceptname="Near syncope">presyncope</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_4a37c80a-d391-47ad-a36c-5a23e6df9821"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_40ea58e7-81f4-40f0-b682-7c31ed300f9c"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Digoxin</h2>
<p class="First">Proarrhythmic events were more common in sotalol treated patients also receiving digoxin; it is not clear whether this represents an interaction or is related to the presence of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, a known risk factor for <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">proarrhythmia</span>, in the patients receiving digoxin. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9eb92c62-4feb-40a0-8592-17dc3e88dcb1"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Calcium Blocking Drugs</h2>
<p class="First">Sotalol and calcium blocking drugs can be expected to have additive effects on atrioventricular conduction, ventricular function, and blood pressure. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ed782acd-13c1-4e6b-8ac1-c8672ea43ef4"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Catecholamine-Depleting Agents</h2>
<p class="First">Concomitant use of catecholamine-depleting drugs, such as reserpine and guanethidine, with a beta-blocker may produce an excessive reduction of resting sympathetic nervous tone. Monitor such patients for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and marked <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> which may produce <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1809d34a-9e6f-46cf-8199-4f8b6d17ad83"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Insulin and Oral Antidiabetic Agents</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. Symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may be masked. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_85751bf5-7492-40f0-a7a4-283a8ac689fd"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Beta-2-Receptor Stimulants</h2>
<p class="First">Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_54326d32-03a6-4901-85ad-2cc0ffe0c4a3"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Clonidine</h2>
<p class="First">Beta-blocking drugs may potentiate the <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">rebound hypertension</span> sometimes observed after discontinuation of clonidine. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_899ceef7-c10f-4308-9b7a-92d7d6091192"></a><a name="section-7.7"></a><p></p>
<h2>7.7 Drugs that Prolong QT Interval and Antiarrhythmic Agents</h2>
<p class="First">Sotalol has not been studied with other drugs that prolong the QT interval, such as antiarrhythmics, some phenothiazines, tricyclic antidepressants, and certain oral macrolides. Class I or Class III antiarrhythmic agents should be withheld for at least three half-lives prior to dosing with sotalol. In clinical trials, sotalol was not administered to patients previously treated with oral amiodarone for &gt;1 month in the previous three months. Class Ia antiarrhythmic drugs, such as disopyramide, quinidine and procainamide and other Class III drugs (e.g., amiodarone) are not recommended as concomitant therapy with intravenous sotalol because of their potential to prolong refractoriness <span class="Italics">[see <a href="#i4i_warnings_precautions_id_ad20e534-fe78-4ebc-859c-1ba09590bed1">Warnings and Precautions (5)</a>]</span>. There is only limited experience with the concomitant use of Class Ib or Ic antiarrhythmics. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_998fdc36-391c-4ee5-adee-57a002b22964"></a><a name="section-7.8"></a><p></p>
<h2>7.8 Other</h2>
<p class="First">No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> were observed with hydrochlorothiazide or warfarin. </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_faef0590-54c2-4a3b-8783-5583b520b19b"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_6b41b3a7-6f07-45a4-83a1-9063185bb0a1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_f28f575d-c612-4b0b-a676-ce25dd659628"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category B</span></p>
<p>There are no adequate and well-controlled studies in pregnant women. Sotalol crosses the placenta. In animal studies there was no increase in congenital anomalies, but an increase in early resorptions occurred at sotalol doses 18 times the maximum recommended human dose (MRHD, based on body surface area). Because, animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
<p>Reproduction studies in rats and rabbits during organogenesis at sotalol doses 9 and 7 times the MRHD (based on body surface area), respectively, did not reveal any increase in congenital abnormalities. In rabbits, a sotalol dose 6 times the MRHD produced a slight increase in <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span>, but this was associated with maternal toxicity. This effect did not occur at a sotalol dose 3 times the MRHD. In rats, a sotalol dose 18 times the MRHD increased the number of early resorptions, while a dose 2.5 times the MRHD produced no increase in early resorptions. </p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_2296f421-39f3-4747-8df8-7a7c2d6d4f9f"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Sotalol is secreted in human milk in high levels. In five mothers whose mean sotalol dose was 433 mg/day, sotalol concentrations in milk ranged from 4.8 to 20.2 mg/L (mean=10.5 mg/L), with a milk:plasma ratio of 5.5:1 (range 2.2-8.8). The calculated infant dose was 0.8-3.4 mg/kg, which is similar to recommended therapeutic doses in neonates. Two other case reports showed similar findings. Because of the potential for adverse reactions in nursing infants from sotalol, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_f3a7416d-508c-4754-9d3a-c2f102f2a8cc"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of sotalol in children have not been established. However, the Class III electrophysiologic and beta-blocking effects, the pharmacokinetics, and the relationship between the effects (QTc interval and resting heart rate) and drug concentrations have been evaluated in children aged between 3 days and 12 years old <span class="Italics">[see <a href="#i4i_clinical_pharmacology_id_9dbc1d13-32c0-4b01-835e-1498c2dd7ab0">Clinical Pharmacology (12)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_c1cd81f0-6449-40d4-855a-132d339383d6"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Intentional or accidental overdosage with sotalol has resulted in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d202dcf2-3f6d-401d-a7a1-f885a57fc44e"></a><a name="section-9.1"></a><p></p>
<p class="First"><span class="Bold">Symptoms and Treatment of Overdosage: </span> The most common signs to be expected are <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. In cases of massive intentional overdosage (2-16 grams) of sotalol the following clinical findings were seen: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, cardiac <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">asystole</span>, prolongation of QT interval, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, and premature ventricular complexes. If overdosage occurs, therapy with sotalol should be discontinued and the patient observed closely. Because of the lack of protein binding, hemodialysis is useful for reducing sotalol plasma concentrations. Patients should be carefully observed until QT intervals are normalized and the heart rate returns to levels &gt;50 bpm. The occurrence of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> following an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may be associated with an initial slow drug elimination phase (half life of 30 hours) thought to be due to a temporary reduction of renal function caused by the <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In addition, if required, the following therapeutic measures are suggested:</p>
<table>
<col width="35%">
<col width="65%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> or Cardiac <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Asystole</span>: </span></p></td>
<td class="Toprule"><p class="First">Atropine, another anticholinergic drug, a beta-adrenergic agonist or transvenous cardiac pacing. </p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">Heart Block</span>: </span></p></td>
<td><p class="First">(second and third degree) transvenous cardiac pacemaker. </p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>: </span></p></td>
<td><p class="First">(depending on associated factors) epinephrine rather than isoproterenol or norepinephrine may be useful. </p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>: </span></p></td>
<td><p class="First">Aminophylline or aerosol beta-2-receptor stimulant. </p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span>: </span></p></td>
<td class="Botrule"><p class="First">DC cardioversion, magnesium sulfate, potassium replacement. Once <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span> is terminated, transvenous cardiac pacing or an isoproterenol infusion to increase heart rate can be employed.</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_50a67b95-b0e5-4459-b7f7-e4bdd2c39f1f"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Sotalol hydrochloride for injection is an aqueous formulation of sotalol hydrochloride for intravenous use. Sotalol is an antiarrhythmic drug with Class II (beta-adrenoreceptor blocking) and Class III (cardiac action potential duration prolongation) properties. </p>
<p>Intravenous sotalol is supplied as a sterile, clear solution in a 10 mL vial, for intravenous administration after dilution. Each vial contains 150 mg racemic sotalol hydrochloride in sodium acetate buffer. The sotalol hydrochloride concentration of the formulation is 15 mg/mL. Each mL contains 2.9 mg glacial acetic acid in water for injection as an inactive ingredient. The pH of the injection is adjusted with sodium hydroxide to be between 6.0 and 7.0. Sotalol hydrochloride is a white, crystalline solid with a molecular weight of 308.8. It is hydrophilic, soluble in water, propylene glycol and ethanol, but is only slightly soluble in chloroform. Chemically, sotalol hydrochloride is </p>
<p>d,l- <span class="Italics">N </span>-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]methane-sulfonamide monohydrochloride. The molecular formula is C<span class="Sub">12 </span>H<span class="Sub">20 </span>N<span class="Sub">2 </span>O<span class="Sub">3</span>S•HCl and is represented by the following structural formula: </p>
<div class="Figure">
<a name="id1827"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2afe7385-2441-4e22-b63e-ab8614b275df&amp;name=1a9b03b5-4401-4e83-bfef-53ba0434e846-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_9dbc1d13-32c0-4b01-835e-1498c2dd7ab0"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_02bd9dc2-4c16-404d-ab02-9e32e6b89bc3"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Sotalol has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. Intravenous sotalol is a racemic mixture of d- and l-sotalol. Both isomers have similar Class III antiarrhythmic effects, while the l-isomer is responsible for virtually all of the beta-blocking activity. The beta-blocking effect of sotalol is non-cardioselective, half maximal at oral doses of about 80 mg/day and maximal at oral doses between 320 and 640 mg/day. Sotalol does not have partial agonist or membrane stabilizing activity. Although significant beta-blockade occurs at oral doses as low as 25 mg, significant Class III effects are seen only at daily doses of 160 mg and above. </p>
<p>In children, a Class III electrophysiological effect can be seen at daily doses of 210 mg/m<span class="Sup">2 </span>body surface area (BSA). A reduction of the resting heart rate due to the beta-blocking effect of sotalol is observed at daily doses ≥90 mg/m<span class="Sup">2 </span>in children. </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_c8a4f3eb-e032-4397-ab51-aae3a35c3b34"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ce9b1bdf-dbd5-457e-bd16-104b9dd19385"></a><a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Bold">Electrophysiology: </span> Sotalol prolongs the plateau phase of the cardiac action potential in the isolated myocyte, as well as in isolated tissue preparations of ventricular or atrial muscle (Class III activity). In intact animals it slows heart rate, decreases AV nodal conduction and increases the refractory periods of atrial and ventricular muscle and conduction tissue.</p>
<p>In man, the Class II (beta-blockade) electrophysiological effects of sotalol are manifested by increased sinus cycle length (slowed heart rate), decreased AV nodal conduction and increased AV nodal refractoriness. The Class III electrophysiological effects in man include prolongation of the atrial and ventricular monophasic action potentials, and effective refractory period prolongation of atrial muscle, ventricular muscle, and atrio-ventricular accessory pathways (where present) in both the anterograde and retrograde directions. With oral doses of 160 to 640 mg/day, the surface ECG shows dose-related mean increases of 40-100 ms in QT and 10-40 ms in QTc. In a study of patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> /flutter (<span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL) receiving three different oral doses of sotalol given q12h (or q24h in patients with a reduced creatinine clearance), mean increases in QT intervals measured from 12-lead ECGs of 25 ms, 40 ms and 54 ms were found in the 80 mg, 120 mg, and 160 mg dose groups, respectively<span class="Italics"> [see <a href="#i4i_section_id_c31b0aa7-3017-4b39-b23a-bbfe8f0fcdbf">Warnings and Precautions (5.1)</a>]</span> No significant alteration in QRS interval was observed. </p>
<p>In a small study (n=25) of patients with implanted defibrillators treated concurrently with sotalol, the average defibrillatory threshold was 6 joules (range 2-15 joules) compared to a mean of 16 joules for a non-randomized comparative group primarily receiving amiodarone.</p>
<p>In a dose-response trial comparing three dose levels of sotalol, 80 mg, 120 mg, and 160 mg with placebo given q12h (or q24h in patients with a reduced renal creatinine clearance) for the prevention of recurrence of symptomatic <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> (<span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>)/flutter (AFL), the mean ventricular rate during recurrence of <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL was 125, 107, 110 and 99 beats/min in the placebo, 80 mg, 120 mg and 160 mg dose groups, respectively (p&lt;0.017) for each sotalol dose group versus placebo). In another placebo controlled trial in which sotalol was titrated to a dose between 160 and 320 mg/day in patients with chronic <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>, the mean ventricular rate during recurrence of <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span> was 107 and 84 beats/min in the placebo and sotalol groups, respectively (p&lt;0.001). </p>
<p>Twenty-five children in an unblinded, multicenter trial with supraventricular (SVT) and/or ventricular (VT) <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmias</span>, aged between 3 days and 12 years (mostly neonates and infants), received an ascending titration regimen with daily doses of 30, 90 and 210 mg/m<span class="Sup">2 </span>with dosing every 8 hours for a total of 9 doses. During steady-state, the respective average increases above baseline of the QTc interval, in ms (%), were 2(+1%), 14(+4%) and 29(+7%) ms at the 3 dose levels. The respective mean maximum increases above baseline of the QTc interval, in ms (%), were 23(+6%), 36(+9%) and 55(+14%) ms at the 3 dose levels. The steady-state percent increases in the RR interval were 3, 9 and 12%. The smallest children (BSA &lt;0.33m<span class="Sup">2</span>) showed a tendency for larger Class III effects (ΔQTc) and an increased frequency of prolongations of the QTc interval as compared with the larger children (BSA ≥0.33m<span class="Sup">2</span>). The beta-blocking effects also tended to be greater in the smaller children (BSA&lt;0.33m<span class="Sup">2</span>). Both the Class III and beta-blocking effects of sotalol were linearly related with the plasma concentrations. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a14f924f-4404-4ab7-941d-219e1d774e97"></a><a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Bold">Hemodynamics: </span> In a study of systemic hemodynamic function measured invasively in 12 patients with a mean LV <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> of 37% and <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> (9 sustained and 3 non-sustained), a median dose of 160 mg twice daily of sotalol produced a 28% reduction in heart rate and a 24% decrease in <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> at 2 hours post-dosing at steady-state. Concurrently, systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and <span class="product-label-link" type="condition" conceptid="4231869" conceptname="Stroke volume">stroke volume</span> showed non-significant increases of 25% and 8%, respectively. Pulmonary capillary wedge pressure increased significantly from 6.4 mmHg to 11.8 mmHg in the 11 patients who completed the study. One patient was discontinued because of worsening <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Mean arterial pressure, mean pulmonary artery pressure and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> work index did not significantly change. Exercise and isoproterenol induced <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> are antagonized by sotalol, and total peripheral resistance increases by a small amount. </p>
<p>In hypertensive patients, sotalol produces significant reductions in both systolic and diastolic blood pressures. Although sotalol is usually well-tolerated hemodynamically, in patients with marginal cardiac compensation, deterioration in cardiac performance may occur. </p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_6c80597f-225c-4ebd-86bc-501959551053"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">In healthy subjects, the oral bioavailability of sotalol is 90-100%. After oral administration, peak plasma concentrations are reached in 2.5 to 4 hours, and steady-state plasma concentrations are attained within 2-3 days (i.e., after 5-6 doses when administered twice daily). Over the oral dosage range 160-640 mg/day sotalol displays dose proportionality with respect to plasma concentrations. Distribution occurs to a central (plasma) and to a peripheral compartment, with a mean elimination half-life of 12 hours. Dosing every 12 hours results in trough plasma concentrations which are approximately one-half of those at peak. </p>
<p>Sotalol does not bind to plasma proteins and is not metabolized. Sotalol shows very little intersubject variability in plasma levels. The pharmacokinetics of the d and l enantiomers of sotalol are essentially identical. Sotalol crosses the blood brain barrier poorly. Excretion is predominantly via the kidney in the unchanged form, and therefore lower doses are necessary in conditions of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#i4i_dosage_admin_id_19f282cf-4239-480c-bf7d-632e7494b94b">Dosage and Administration (2)</a>].</span></p>
<p>Age per se does not significantly alter the pharmacokinetics of sotalol, but <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> in geriatric patients can increase the terminal elimination half-life, resulting in increased drug accumulation. The absorption of sotalol was reduced by approximately 20% compared to fasting when it was administered with a standard meal. Since sotalol is not subject to first-pass metabolism, patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> show no alteration in clearance of sotalol. </p>
<p>The combined analysis of two unblinded, multicenter trials (a single dose and a multiple dose study) with 59 children, aged between 3 days and 12 years, showed the pharmacokinetics of sotalol to be first order. A daily dose of 30 mg/m<span class="Sup">2 </span>of sotalol was administered in the single dose study and daily doses of 30, 90 and 210 mg/m<span class="Sup">2 </span>were administered q8h in the multi-dose study. After rapid absorption with peak levels occurring on average between 2-3 hours following administration, sotalol was eliminated with a mean half-life of 9.5 hours. Steady-state was reached after 1-2 days. The average peak to trough concentration ratio was 2. BSA was the most important covariate and more relevant than age for the pharmacokinetics of sotalol. The smallest children (BSA &lt;0.33 m<span class="Sup">2</span>) exhibited a greater drug exposure (+59%) than the larger children who showed a uniform drug concentration profile. The intersubject variation for oral clearance was 22%. </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_19015afc-c9d9-4cf0-b8a2-471f2714230a"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_b39e0177-7350-408a-a513-311e30903626"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No evidence of carcinogenic potential was observed in rats during a 24-month study at 137-275 mg/kg/ day (approximately 30 times the maximum recommended human oral dose (MRHD) as mg/kg or 5 times the MRHD as mg/m<span class="Sup">2</span>) or in mice, during a 24-month study at 4141-7122 mg/kg/day (approximately 450-750 times the MRHD as mg/kg or 36-63 times the MRHD as mg/m<span class="Sup">2</span>). Sotalol has not been evaluated in any specific assay of mutagenicity or clastogenicity. </p>
<p>No significant reduction in fertility occurred in rats at oral doses of 1000 mg/kg/day (approximately 100 times the MRHD as mg/kg or 9 times the MRHD as mg/m<span class="Sup">2</span>) prior to mating, except for a small reduction in the number of offspring per litter. </p>
<p>Reproduction studies in rats and rabbits during organogenesis at 100 and 22 times the MRHD as mg/kg (9 and 7 times the MRHD as mg/m<span class="Sup">2</span>), respectively, did not reveal any teratogenic potential associated with sotalol HCl. In rabbits, a high dose of sotalol HCl (160 mg/kg/day) at 16 times the MRHD as mg/kg (6 times the MRHD as mg/m<span class="Sup">2</span>) produced a slight increase in <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> likely due to maternal toxicity. Eight times the maximum dose (80 mg/kg/day or 3 times the MRHD as mg/m<span class="Sup">2</span>) did not result in an increased incidence of <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span>. In rats, 1000 mg/kg/day sotalol HCl, 100 times the MRHD (18 times the MRHD as mg/m<span class="Sup">2</span>), increased the number of early resorptions, while at 14 times the maximum dose (2.5 times the MRHD as mg/m<span class="Sup">2</span>), no increase in early resorptions was noted. However, animal reproduction studies are not always predictive of human response. </p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_8eb6e171-0b36-42c0-a583-ac3ddc254db4"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">The LD50 of sotalol has been established in a variety of species. As the data in Table 5 show, LD<span class="Sub">50</span> is 100 to 1000 times more than the regular therapeutic dose:</p>
<a name="_Reftable5"></a><table>
<caption><span>Table 5: The LD50 of Sotalol in Different Species</span></caption>
<col width="40%">
<col width="30%">
<col width="30%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" valign="top"><span class="Bold">Route of Administration</span></th>
<th class="Botrule Rrule Toprule" valign="top"><span class="Bold">Species</span></th>
<th class="Botrule Rrule Toprule" valign="top"><span class="Bold">LD<span class="Sub">50</span></span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Oral</p></td>
<td class="Botrule Rrule Toprule"><p class="First">Rat</p></td>
<td class="Botrule Rrule Toprule"><p class="First">3450 mg/kg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Oral</p></td>
<td class="Botrule Rrule"><p class="First">Mouse</p></td>
<td class="Botrule Rrule"><p class="First">2600 mg/kg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Oral</p></td>
<td class="Botrule Rrule"><p class="First">Rabbit</p></td>
<td class="Botrule Rrule"><p class="First">1000 mg/kg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Intraperitoneal</p></td>
<td class="Botrule Rrule"><p class="First">Rat</p></td>
<td class="Botrule Rrule"><p class="First">680 mg/kg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Intraperitoneal</p></td>
<td class="Botrule Rrule"><p class="First">Mouse</p></td>
<td class="Botrule Rrule"><p class="First">670 mg/kg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Intraperitoneal</p></td>
<td class="Botrule Rrule"><p class="First">Dog</p></td>
<td class="Botrule Rrule"><p class="First">330 mg/kg</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Intravenous</p></td>
<td class="Botrule Rrule"><p class="First">Mouse</p></td>
<td class="Botrule Rrule"><p class="First">166 mg/kg</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_e0abede8-e0cf-4c0d-8b60-e58e7c52abbe"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">There is no clinical experience with intravenous sotalol. However, because of the similarity of exposure of intravenous sotalol to oral sotalol, the expectation is that the efficacy will be similar.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d958342c-a0db-4cea-8fac-1f3cd1f0ffb6"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Clinical Studies in <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular Arrhythmias</span></h2>
<p class="First">Sotalol has been studied in life-threatening and less severe <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>. In patients with frequent premature ventricular complexes (VPC), orally administered sotalol was significantly superior to placebo in reducing VPCs, paired VPCs and non-<span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">sustained ventricular tachycardia</span> (NSVT); the response was dose-related through 640 mg/day with 80-85% of patients having at least a 75% reduction of VPCs. Sotalol was also superior, at the doses evaluated, to propranolol (40-80 mg TID) and similar to quinidine (200-400 mg QID) in reducing VPCs. In patients with life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> [<span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">sustained ventricular tachycardia</span>/<span class="product-label-link" type="condition" conceptid="4226399" conceptname="Fibrillation">fibrillation</span> (VT/VF)], sotalol was studied acutely [by suppression of programmed electrical stimulation (PES) induced VT and by suppression of Holter monitor evidence of sustained VT] and, in acute responders, chronically.</p>
<p>In a double-blind, randomized comparison of oral sotalol and procainamide given intravenously (total of 2 mg/kg sotalol vs. 19 mg/kg of procainamide over 90 minutes), sotalol suppressed PES induction in 30% of patients vs. 20% for procainamide (p=0.2).</p>
<p>In a randomized clinical trial [Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Trial] comparing choice of antiarrhythmic therapy by PES suppression vs. Holter monitor selection (in each case followed by treadmill exercise testing) in patients with a history of sustained VT/VF who were also inducible by PES, the effectiveness acutely and chronically of sotalol was compared with 6 other drugs (procainamide, quinidine, mexiletine, propafenone, and imipramine). Overall response, limited to first randomized drug, was 39% for sotalol and 30% for the pooled other drugs. Acute response rate for first drug randomized using suppression of PES induction was 36% for sotalol vs. a mean of 13% for the other drugs. Using the Holter monitoring endpoint (complete suppression of sustained VT, 90% suppression of NSVT, 80% suppression of VPC pairs, and at least 70% suppression of VPCs), sotalol yielded 41% response vs. 45% for the other drugs combined. Among responders placed on long term therapy identified acutely as effective (by either PES or Holter), Sotalol, when compared to the pool of other drugs, had the lowest two-year mortality (13% vs. 22%), the lowest two-year VT recurrence rate (30% vs. 60%), and the lowest withdrawal rate (38% vs. about 75-80%). The most commonly used doses of sotalol in this trial were 320-480 mg/day (66% of patients), with 16% receiving 240 mg/day or less and 18% receiving 640 mg or more. It cannot be determined, however, in the absence of a controlled comparison of sotalol vs. no pharmacologic treatment (e.g., in patients with implanted defibrillators) whether sotalol response causes improved survival or identifies a population with a good prognosis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9a70ce44-6aa5-4ba7-9f58-2abc92d9cb22"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Clinical Studies in Supra-<span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular Arrhythmias</span></h2>
<p class="First">Orally administered sotalol has been studied in patients with symptomatic <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL in two principal studies, one in patients with primarily paroxysmal <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL, the other in patients with primarily chronic <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>. </p>
<p>In one study, a U.S. multicenter, randomized, placebo-controlled, double-blind, dose-response trial of patients with symptomatic primarily paroxysmal <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL, three fixed dose levels of sotalol (80 mg, 120 mg and 160 mg) twice daily and placebo were compared in 253 patients. In patients with reduced creatinine clearance (40-60 mL/min) the same doses were given once daily. Patients were not randomized for the following reasons: QT &gt;450 ms; creatinine clearance &lt;40 mL/min; intolerance to beta-blockers; <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>-<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> syndrome in the absence of an implanted pacemaker; <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL was asymptomatic or was associated with <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, embolic CVA or TIA; <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> within the previous 2 months; <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>; bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or other contraindications to beta-blocker therapy; receiving potassium losing diuretics without potassium replacement or without concurrent use of ACE-inhibitors; uncorrected <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (serum potassium &lt;3.5 meq/L) or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> (serum magnesium &lt;1.5 meq/L); received chronic oral amiodarone therapy for &gt;1 month within previous 12 weeks; congenital or acquired <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndromes</span>; history of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span> with other antiarrhythmic agents which increase the duration of ventricular repolarization; sinus rate &lt;50 bpm during waking hours; <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> pectoris; receiving treatment with other drugs that prolong the QT interval; and <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL associated with the Wolff-Parkinson-White (WPW) syndrome. If the QT interval increased to ≥520 ms (or JT ≥430 ms if QRS &gt;100 ms) the drug was discontinued. The patient population in this trial was 64% male, and the mean age was 62 years. No structural heart disease was present in 43% of the patients. Doses were administered once daily in 20% of the patients because of reduced creatinine clearance. </p>
<p>Sotalol was shown to prolong the time to the first symptomatic, ECG-documented recurrence of <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL, as well as to reduce the risk of such recurrence at both 6 and 12 months. The 120 mg dose was more effective than 80 mg, but 160 mg did not appear to have an added benefit. Note that these doses were given twice or once daily, depending on renal function. The results are shown in Figure 1 and Tables 6 and 7. </p>
<div class="Figure">
<a name="id1998"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2afe7385-2441-4e22-b63e-ab8614b275df&amp;name=1a9b03b5-4401-4e83-bfef-53ba0434e846-03.jpg">
</div>
<p></p>
<a name="_Reftable6"></a><table>
<caption><span>Table 6: Study 1 - Patient Status at 12 Months</span></caption>
<col width="37%">
<col width="14%">
<col width="36%">
<col width="14%">
<col width="14%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"></th>
<th class="Botrule Rrule Toprule" rowspan="2" valign="top"><span class="Bold">Placebo </span></th>
<th class="Botrule Rrule Toprule" colspan="3" valign="top"><span class="Bold">Oral Sotalol Dose </span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" valign="top"><span class="Bold">80 mg </span></th>
<th class="Botrule Rrule" valign="top"><span class="Bold">120 mg </span></th>
<th class="Botrule Rrule" valign="top"><span class="Bold">160 mg </span></th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Symptomatic <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>Efficacy endpoint of Study 1; study treatment stopped.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Randomized </p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First">69 </p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First">59 </p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First">63 </p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First">62 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">On treatment in NSR at 12 months without recurrence <a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">23% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">22% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">29% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">23% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Recurrence <a href="#footnote-3" class="Sup">*</a><span class="Sup">, </span><a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">67% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">58% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">49% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">42% </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">D/C for AEs </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">6% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">12% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">18% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">29% </p></td>
</tr>
</tbody>
</table>
<p>Note that columns do not add up to 100% due to discontinuations (D/C) for "other" reasons. </p>
<a name="_Reftable7"></a><table>
<caption><span>Table 7: Study 1 - Median Time to Recurrence of Symptomatic <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL and Relative Risk (vs. Placebo) at 12 Months</span></caption>
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"></th>
<th class="Botrule Rrule Toprule" rowspan="2" valign="middle"><span class="Bold">Placebo </span></th>
<th class="Botrule Rrule Toprule" colspan="3" valign="top"><span class="Bold">Oral Sotalol Dose </span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" valign="top"><span class="Bold">80 mg </span></th>
<th class="Botrule Rrule" valign="top"><span class="Bold">120 mg </span></th>
<th class="Botrule Rrule" valign="top"><span class="Bold">160 mg </span></th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First">p-value vs. placebo </p></td>
<td class="Botrule Rrule Toprule" valign="middle"></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First">p=0.325 </p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First">p=0.018 </p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First">p=0.029 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Relative Risk (RR) to placebo </p></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.81 </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.59 </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.59 </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Median time to recurrence (days) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">27 </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">106 </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">229 </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">175 </p></td>
</tr>
</tbody>
</table>
<p>Discontinuation because of adverse events was dose related. </p>
<p>In a second multicenter, randomized, placebo-controlled, double-blind study of 6 months duration in 232 patients with chronic <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>, sotalol was titrated over a dose range from 80 mg/day to 320 mg/day. The patient population of this trial was 70% male with a mean age of 65 years. Structural heart disease was present in 49% of the patients. All patients had chronic <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span> for &gt;2 weeks but &lt;1 year at entry with a mean duration of 4.1 months. Patients were excluded if they had significant <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, QTc &gt;460 ms, QRS &gt;140 ms, any degree of <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> or functioning pacemaker, uncompensated <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, significant <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (estimated creatinine clearance &lt;50 mL/min), heart rate &lt;50 bpm, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or open heart surgery in past 2 months, <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span>, infective <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span>, active <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span> or <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, ≥3 DC cardioversions in the past, medications that prolonged QT interval, and previous amiodarone treatment. After successful cardioversion patients were randomized to receive placebo (n=114) or sotalol (n=118), at a starting dose of 80 mg twice daily. If the initial dose was not tolerated it was decreased to 80 mg once daily, but if it was tolerated it was increased to 160 mg twice daily. During the maintenance period 67% of treated patients received a dose of 160 mg twice daily, and the remainder received doses of 80 mg once daily (17%) and 80 mg twice daily (16%). </p>
<p>Figure 2 and Tables 8 and 9 show the results of the trial. There was a longer time to ECG-documented recurrence of <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span> and a reduced risk of recurrence at 6 months compared to placebo. </p>
<a name="_Reftable8"></a><table>
<caption><span>Table 8: Study 2 - Patient Status at 6 Months</span></caption>
<col width="40%">
<col width="40%">
<col width="30%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"><span class="Bold">Randomized </span></th>
<th class="Botrule Rrule Toprule" valign="middle"><span class="Bold">Oral Sotalol </span></th>
<th class="Botrule Rrule Toprule" valign="middle"><span class="Bold">Placebo </span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" valign="middle"><span class="Bold">118 </span></th>
<th class="Botrule Rrule" valign="middle"><span class="Bold">114 </span></th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Symptomatic or asymptomatic <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>Efficacy endpoint of Study 2; study treatment stopped.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First">On treatment in NSR at 6 months without recurrence <a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First">45% </p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First">29% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Recurrence <a href="#footnote-5" class="Sup">*</a><span class="Sup">, </span><a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">49% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">67% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">D/C for AEs </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">6% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">3% </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> </p></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1% </p></td>
</tr>
</tbody>
</table>
<a name="_Reftable9"></a><table>
<caption><span>Table 9: Study 2 - Median Time to Recurrence of Symptomatic <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">AFIB</span>/AFL/<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> and Relative Risk (vs. Placebo) at 6 Months</span></caption>
<col width="40%">
<col width="40%">
<col width="30%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"><span class="Bold">p-value vs. placebo </span></th>
<th class="Botrule Rrule Toprule" valign="middle"><span class="Bold">Oral Sotalol </span></th>
<th class="Botrule Rrule Toprule" valign="middle"><span class="Bold">Placebo </span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" valign="middle"><span class="Bold">p=0.002 </span></th>
<th class="Botrule Rrule" valign="middle"></th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule"><p class="First">Relative Risk (RR) to placebo </p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First">0.55 </p></td>
<td class="Botrule Rrule Toprule" valign="middle"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Median time to recurrence (days) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">&gt;180 </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">44 </p></td>
</tr>
</tbody>
</table>
<div class="Figure">
<a name="id2139"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2afe7385-2441-4e22-b63e-ab8614b275df&amp;name=1a9b03b5-4401-4e83-bfef-53ba0434e846-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_755ac418-2b7a-4cab-8fc3-e197ea59723f"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Clinical Studies in Patients with <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></h2>
<p class="First">In a multicenter double-blind randomized study reported by Julian et al, the effect of sotalol 320 mg once daily was compared with that of placebo in 1456 patients (randomized 3:2, sotalol to placebo) surviving an <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> (MI). Treatment was started 5-14 days after <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>. Patients were followed for 12 months. The mortality rate was 7.3% in the sotalol group and 8.9% in the placebo group, not a statistically significant difference. Although the results do not show evidence of a benefit of sotalol in this population, they do not show an added risk in <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">post MI</span> patients receiving sotalol. There was, however, a suggestion of an early (i.e., first 10 days) excess mortality (3% on sotalol vs. 2% on placebo). </p>
<p>In a second small trial (n=17 randomized to sotalol) where sotalol was administered at high doses (e.g., 320 mg twice daily) to high-risk post-<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> patients (<span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> &lt;40% and either &gt;10 VPC/hr or VT on Holter), there were 4 fatalities and 3 serious hemodynamic/electrical adverse events within two weeks of initiating sotalol.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_d5628424-58c3-4e0a-acf7-ded2bfe4fb5d"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Intravenous sotalol is supplied in 10 mL vials, each containing 150 mg of sotalol hydrochloride (15 mg/mL). </p>
<p>NDC 67457-176-10<br>carton containing one, 10 mL vial</p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_4897fc00-f049-4907-9fd4-16e94d74ffe8"></a><a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</span><br><span class="Bold">Protect from freezing and light.</span></p>
<p>Manufactured by:<br><span class="Bold">Mylan Institutional</span><br>Galway, Ireland</p>
<p>Manufactured for:<br><span class="Bold">Academic Pharmaceuticals Inc.</span><br>21 N. Skokie Highway<br>Suite G-3<br>Lake Bluff, IL 60044 U.S.A.</p>
<p>Distributed by:<br><span class="Bold">ALTATHERA Pharmaceuticals LLC<br></span>Chicago, IL 60606 U.S.A.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_b4649326-3113-4b91-bc6c-9265c9cb1583"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Instruct patients to report syncopal events or new pre-syncopal symptoms, as these may be signs of either <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span>.</p>
<p>Instruct patients to inform a nurse or physician if <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> develop at the infusion site, or if an alarm sounds from the infusion pump.</p>
<p>REVISED AUGUST 2014<br>MI:SOTAIJ:R2<br>0676L102</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_f35a65ae-e388-4b0f-86f5-3d8212eb8ee6"></a><a name="section-16"></a><p></p>
<h1>      </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton</span></p>
<p><span class="Bold">NDC 67457-176-10     10 mL</span></p>
<p><span class="Bold">Sotalol</span><br><span class="Bold">Hydrochloride</span><br><span class="Bold">Injection<br>150 mg/10 mL</span><br>(15 mg/mL)</p>
<p><span class="Bold">For Intravenous Use Only</span></p>
<p><span class="Bold">Rx only      Single-Dose Vial</span></p>
<p><span class="Bold">Store at 20° to 25°C</span><br><span class="Bold">(68° to 77°F). [See USP</span><br><span class="Bold">Controlled Room</span><br><span class="Bold">Temperature.] Protect from</span><br><span class="Bold">freezing and light.</span></p>
<p>Store the vial in its original<br>carton until ready to use.</p>
<p>Manufactured by:<br><span class="Bold">Mylan Institutional</span><br>Galway, Ireland</p>
<p>Manufactured for:<br><span class="Bold">Academic Pharmaceuticals Inc.</span><br>21 N. Skokie Highway<br>Suite G-3<br>Lake Bluff, IL 60044 U.S.A.</p>
<p>Distributed by:<br><span class="Bold">ALTATHERA Pharmaceuticals LLC<br></span>Chicago, IL 60606 U.S.A.</p>
<p>MI:176:1C:R2</p>
<p><span class="Bold">Mylan.com</span></p>
<p>Sterile. Pyrogen Free.</p>
<p><span class="Bold">Each mL contains:</span> Sotalol<br>Hydrochloride 15 mg;<br>Water for Injection q.s.;<br>Glacial Acetic Acid 2.9 mg.</p>
<p><span class="Bold">Usual Dosage:</span> Administer<br>as a slow infusion over 5<br>hours. See accompanying<br>prescribing information.</p>
<div class="Figure">
<a name="id2266"></a><img alt="Sotalol Hydrochloride Injection 150 mg/10 mL (15 mg/mL) Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2afe7385-2441-4e22-b63e-ab8614b275df&amp;name=1a9b03b5-4401-4e83-bfef-53ba0434e846-05.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SOTALOL HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">sotalol hydrochloride injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67457-176</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Sotalol hydrochloride</strong> (Sotalol) </td>
<td class="formItem">Sotalol hydrochloride</td>
<td class="formItem">15 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>acetic acid</strong></td>
<td class="formItem">2.9 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-176-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022306</td>
<td class="formItem">09/30/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Institutional LLC
							(790384502)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>79325341-258f-4ad1-b554-8b51512f0e9f</div>
<div>Set id: 2afe7385-2441-4e22-b63e-ab8614b275df</div>
<div>Version: 4</div>
<div>Effective Time: 20140917</div>
</div>
</div> <div class="DistributorName">Mylan Institutional LLC</div></p>
</body></html>
